🇺🇸 FDA
Patent

US 8541403

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

granted A61KA61K31/5025A61K31/5377

Quick answer

US patent 8541403 (Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
38
CPC classes
A61K, A61K31/5025, A61K31/5377, A61K45/06, A61P